Melanoma vaccine forges ahead

Nov 01, 2004, 5:00am

Z?rich - Among skin cancer vaccines, Canvaxin (CancerVax Corp.) stands alone for reasons that include its unique profile of immunopotent antigens and its evidence for potential efficacy in extensive phase 2 testing. Perhaps more importantly, Canvaxin is currently the only skin cancer vaccine that's in large-scale phase 3 randomized postsurgical adjuvant trials for patients with stage 3 and 4 melanoma. These studies, if positive, will provide the necessary efficacy and safety data to support marketing approval.